CureVac NV and its partner GSK Plc have reported promising preliminary data from ongoing Phase 1 studies of vaccine candidates directed against both Covid-19 and influenza. The experimental medicines are based on messenger RNA. The results showed that vaccine candidates using a modified second-generation mRNA backbone produced promising immunogenicity and reactogenicity profiles in both indications. The modified vaccines are directed against specific antigens.
